Tulane Home Tulane Shield logo linking to site home page

Prostate Clinical Trials

Molecularly Targeted Radiation Trials
 

AAA
Phase 1/2 Open-Label, Multi-Center, Dose-Escalation Study of Safety, Tolerability, Pharmacokinetics, Dosimetry, and Response to Repeat Dosing of 177Lu-PSMA-R2 Radio-Ligand Therapy in Patients with Prostate Specific Membrane Antigen (PSMA) Positive (68Ga-PSMA-R2) Progressive Metastatic Castration-Resistant Prostate Cancer, Following Previous Systemic Treatment
More Information

ARROW        
A multicenter, Randomized, controlled phase 2 study: Efficacy and safety of I-131-1095 Radiotherapy in combination with enzalutamide in metastatic castration-resistant prOstate cancer (mCRPC) patients Who are 18F-DCFPyL prostate-specific membrane antigen (PSMA)-avid, chemotherapy-naïve, and progressed on abiraterone
More Information

BED IIT-382    
Changes in 18F-fluciclovine Positron Emission Tomography (PET) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate: A Pilot Study
More Information

ESCALATE
A Phase III Randomized Study Comparing Enzalutamide or Darolutamide with Radium-223 vs Enzalutamide or Darolutamide with Placebo and the Effect upon Symptomatic Skeletal Event-Free Survival for mCRPC Patients
More Information

FIREFLY-IIT
Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer -NCT03976843

Bayer 19445
A phase 1 open label, first-in-human, multi-center, study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of a thorium-2227 labeled antibody-chelator conjugate, BAY 2315497 Injection, along and in combination with darolutamide (BAY 1841788) in patients with metastatic castration prostate cancer

69086420PCR1001 HOXTON
A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
More Information

 

Other Prostate Cancer Trials

NRG GU005 - NCT03367702
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

NU 17U19
Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

TCBIO-001-0710
The Caris Biorepository Research Protocol

TUHC 07/25/13 - Genetics of Prostate Cancer

IRONMAN
Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)
More Information

Merck 641
A Phase 3, Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
More Information

C17-191         
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in Metastatic Castration Sensitive Prostate Cancer with and without DNA Repair Mutations. (CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone.)
More Information

AMGEN 509
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
More Information

AMGEN 160
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-Life Extended Bispecific T-Cell Engager AMG 160 in Subjects with Metastatic Castration-Resistant Prostate Cancer
More Information

ARV-110-mCRPC-101
A Phase 1/2, open-label, dose escalation, and cohort expansion clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration resistant prostate cancer

PLANETTE
A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations